S100A9 and cancer: To evaluate the clinical assessment of DAMPs as candidate predictive biomarkers, the diagnostic efficiencies of serum HMGB1, HSP90, and S100A9 in M0 and M1 cancer patients were assessed with ROC curve analysis (Figure 2).